Filtered By:
Nutrition: Calcium
This page shows you your search results in order of date.
Order by Relevance | Date
Total 57 results found since Jan 2013.
Adverse Association Identified for Calcium Channel Blocker Use, Glaucoma
FRIDAY, Sept. 8, 2023 -- There is an adverse association between calcium channel blocker (CCB) use and glaucoma, according to a study published online Sept. 7 in JAMA Ophthalmology.
Alan Kastner, M.D., from Moorfields Eye Hospital National Health...
Source: Drugs.com - Pharma News - September 8, 2023 Category: Pharmaceuticals Source Type: news
Calcium Channel Blockers Again Linked to Glaucoma
(MedPage Today) -- Patients on calcium channel blockers (CCBs) had a higher likelihood of glaucoma than their counterparts, according to a population-based, cross-sectional study.
Examining data on more than 400,000 participants in the U.K. Biobank...
Source: MedPage Today Cardiovascular - September 7, 2023 Category: Cardiology Source Type: news
Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations
AbstractDue to the diverse mechanisms of action of antiseizure drugs, there has been a rise in prescriptions of these drugs for non-epileptic pathologies. One drug that is now being used for a variety of conditions is topiramate. This is a narrative review that used PubMed, Google Scholar, MEDLINE, and ScienceDirect to review literature on the clinical and pharmacologic properties of topiramate. Topiramate is a commonly prescribed second-generation antiseizure drug. The drug works through multiple pathways to prevent seizures. In this regard, topiramate blocks sodium and calcium voltage-gated channels, inhibits glutamate r...
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research
New Evidence Links Calcium Channel Blockers to Increased Risk of Glaucoma
(MedPage Today) -- Use of calcium channel blockers (CCBs), particularly cardioselective agents, had a modest but statistically significant association with glaucoma, a large meta-analysis showed.
Overall, patients with a history of CCB treatment...
Source: MedPage Today Cardiovascular - June 14, 2023 Category: Cardiology Source Type: news
A Systematic Review and Meta-Analysis of Systemic Antihypertensive Medications with Intraocular Pressure and Glaucoma
: We synthesized the literature on the association between systemic antihypertensive medications with intraocular pressure (IOP) and glaucoma. Antihypertensive medications included beta blockers (BB), calcium channel blockers (CCB), angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), and diuretics.
Source: American Journal of Ophthalmology - March 24, 2023 Category: Opthalmology Authors: Gareth Leung, Alyssa Grant, Andrew N. Garas, Gisele Li, Ellen E. Freeman Source Type: research
L- and T-type Ca < sup > 2+ < /sup > channels dichotomously contribute to retinal ganglion cell injury in experimental glaucoma
In this study, we found that total Ca2+ current densities in retinal ganglion cells were reduced in a rat model of chronic ocular hypertension experimental glaucoma, as determined by whole-cell patch-clamp electrophysiological recordings. Further analysis showed that L-type Ca2+ currents were downregulated while T-type Ca2+ currents were upregulated at the later stage of glaucoma. Western blot assay and immunofluorescence experiments confirmed that expression of the CaV1.2 subunit of L-type Ca2+ channels was reduced and expression of the CaV3.3 subunit of T-type Ca2+ channels was increased in retinas of the chronic ocular ...
Source: Cell Research - December 26, 2022 Category: Cytology Authors: Hong-Ning Wang Wen-Jing Qian Guo-Li Zhao Fang Li Yan-Ying Miao Bo Lei Xing-Huai Sun Zhong-Feng Wang Source Type: research
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Role of CAST-Drp1 Pathway in Retinal Neuron-Regulated Necrosis in Experimental Glaucoma
ConclusionThe results of this study indicate that the CAST-Drp1 pathway protects against retinal neuron-regulated necrosis, which may expand the therapeutic targets for the treatment of neurodegenerative disorders involving dysfunction of glutamate metabolism, such as glaucoma.
Source: Journal of Huazhong University of Science and Technology -- Medical Sciences -- - October 17, 2022 Category: Research Source Type: research
Retinal TRP channels: Cell-type-specific regulators of retinal homeostasis and multimodal integration
This article surveys current knowledge about the expression and function of the TRP family in vertebrate retinas, which, while dedicated to transduction and transmission of visual information, are highly susceptible to non-visual stimuli. Every retinal cell expresses multiple TRP subunits, with recent evidence establishing their critical roles in paradigmatic aspects of vertebrate vision that include TRPM1-dependent transduction of ON bipolar signaling, TRPC6/7-mediated ganglion cell phototransduction, TRP/TRPL phototransduction in Drosophila and TRPV4-dependent osmoregulation, mechanotransduction, and regulation of inner ...
Source: Cell Research - September 26, 2022 Category: Cytology Authors: David Kri žaj Soenke Cordeiro Olaf Strau ß Source Type: research
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX ® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
LOS ANGELES, August 27, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study evaluating the investigational use of DARZALEX® (daratumumab) in combination with lenalidomide (Revlimid®), bortezomib (VELCADE®) and dexamethasone (DARZALEX®-RVd), followed by maintenance therapy with DARZALEX®-lenalidomide (R), compared to RVd followed by maintenance therapy with R alone, in patients with newly diagnosed, transplant-eligible multiple myeloma. Data were presented in the plenary session at the 19th International Myeloma Society (IMS)...
Source: Johnson and Johnson - August 28, 2022 Category: Pharmaceuticals Source Type: news
Calcium dysregulation potentiates wild-type myocilin misfolding: implications for glaucoma pathogenesis
This study explores the effect of calcium depletion on myocilin olfactomedin domain folding.PMID:35831671 | DOI:10.1007/s00775-022-01946-3
Source: Journal of Biological Inorganic Chemistry : JBIC - July 13, 2022 Category: Chemistry Authors: Emily G Saccuzzo Mackenzie D Martin Kamisha R Hill Minh Thu Ma Yemo Ku Raquel L Lieberman Source Type: research
Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
TMCO1 expression promotes cell proliferation and induces epithelial –mesenchymal transformation in human gliomas
This study demonstrated that TMCO1 was upregulated in gliomas and its overexpression predicted poor prognosis. We also revealed that the expression of TMCO1 was associated with the World Health Organization (WHO) grade of gliomas. Knockdown of TMCO1 inhibited the proliferation and induced apoptosis of U87 and U251 cells. In addition, TMCO1 induced GBM cell migration and invasion by promoting epithelial –mesenchymal transition (EMT). These date collectively proved the crucial role of TMCO1 as a novel prognostic factor and underlying therapeutic target for glioma patients.
Source: Medical Oncology - May 15, 2022 Category: Cancer & Oncology Source Type: research
